OUR COMPANY

Gecko is a privately owned life science company developing innovative polymer solutions for Tissue Reconstruction. The company has developed a fully industrialised platform allowing the swift development of proprietary medical devices around its polymer families. Its platform is currently focusing on cardiovascular, bone, nerve, ophthalmic and urology applications.

A first product has been CE marked in 2017 for application in vascular reconstruction.

Gecko’s vision is to create an ecosystem around its versatile technology platform that will drive innovation in Tissue Reconstruction. Our ecosystem will streamline innovation:

  • By leveraging our expertise on tissues and design of delivery devices for our internal program,
  • But also through strategic partnerships around our family of polymers and delivery technologies,
  • In our core therapeutic areas (cardiovascular, bone, nerve, ophthalmology, urology),
  • By expending on the breath of functionality from our platform (Tissue guiding, adhesives, sealants, barrier, filler, 3D printed bioresorbable devices but also localized drug delivery).

The Company’s technology is based on world-class research and intellectual property from the laboratories of Pr Robert Langer (MIT) and Pr Jeff Karp (Brigham and Women’s Hospital), who co-founded the company in 2013.

Management

Board of Directors


Scientific advisors


Investors

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, the firm brings together 12 highly experienced investment professionals from all over Europe, the US and China.

Bpifrance, a subsidiary of the Caisse des Dépôts and the French State, a trusted partner for entrepreneurs, supports companies from start-up to their listing on the stock market, through credit, guarantees and equity.

CM-CIC Capital Innovation is specialized in investment and support for high-potential growth companies, with strong technology expertise, in the first stages of their development. It finances firms positioned on sectors such as life sciences, and industrial innovations or environment.

Omnes Capital is a major player in private equity, with a commitment to financing SMEs. With €1.9 billion in assets under management, Omnes Capital provides companies with the capital needed to finance their growth. Omnes Capital, was a subsidiary of Crédit Agricole until it March 2012.

CapDecisif Management is a management company investing in high-potential innovative companies in the sectors of information and communication technology, life sciences, energy and the environment, mainly in the Paris region. Its team was brought together in 2001 and has remained intact since.

Investors

Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, the firm brings together 12 highly experienced investment professionals from all over Europe, the US and China.

Bpifrance, a subsidiary of the Caisse des Dépôts and the French State, a trusted partner for entrepreneurs, supports companies from start-up to their listing on the stock market, through credit, guarantees and equity.

CM-CIC Capital Innovation is specialized in investment and support for high-potential growth companies, with strong technology expertise, in the first stages of their development. It finances firms positioned on sectors such as life sciences, and industrial innovations or environment.

Omnes Capital is a major player in private equity, with a commitment to financing SMEs. With €1.9 billion in assets under management, Omnes Capital provides companies with the capital needed to finance their growth. Omnes Capital, was a subsidiary of Crédit Agricole until it March 2012.

CapDecisif Management is a management company investing in high-potential innovative companies in the sectors of information and communication technology, life sciences, energy and the environment, mainly in the Paris region. Its team was brought together in 2001 and has remained intact since.